IM-T9P1 / Secarna - LARVOL DELTA

Secarna Pharmaceuticals Announces Publication of New Preclinical Data Showing Durable Antitumor Activity of LNAplus-Based ASOs that Both Stimulate the Innate Immune System and Suppress PD-L1 Expression (Yahoo Finance) - "Secarna Pharmaceuticals...announced the publication of striking new preclinical data demonstrating that bimodal ASOs can enable efficacious long-term antitumor immunity in tumor models compared to current immune checkpoint inhibitors....The publication describes the preclinical activity of Secarna's high-affinity bimodal LNAplus™-based ASO, IM-T9P1, that simultaneously triggers toll-like receptor 9 (TLR9) signaling and downregulates programmed cell death ligand 1 (PD-L1) expression, a protein involved in the suppression of the adaptive immune system, in one molecular entity. TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens."

Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor